PDF
ePub
Citation
Print
Abstract
To evaluate the efficacy and safety of lovastatin, new hypolipidemic agent of HMG-CoA reductase inhibitor, we administered lovastatin 40mg to 80mg once daily for 12 weeks in 20 patients(7 males, 13 females) with primary hypercholesterolemia, and observed the sequential chamges of the lipid profile every 4 weeks.
The results are as follows ;
1) The seurm total cholesterol was reduced significantly by 31% from 321±36mg% to 210±26mg%(p<0.05).
2) The serum triglycerides was significantly reduced from 321±168mg% to 228±74mg% by 29%(p<0.05).
3) The low density lipoprotein cholesterol was reduced significantly from 177±36mg% to 120±22mg% by 32%(p<0.05).
4) The total lipid, high density lipoprotein cholesterol and very low density lipoprotein cholesterol were also reduced significantly.
5) The ratio between total cholesterol and high density lipoprotein cholesterol, low density lipoprotein cholesterol and high density lipoprotein cholesterol did not change after lovastatin therapy.
6) There was no adverse reaction due to lovastatin therapy during 12 weeks of therapy.
These results suggested that lovastatin is a effective and safe now hypolipidemic agent and is a convenient HMG-CoA reductase inhibitor for clinical use.
XML Download